<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151565">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126970</url>
  </required_header>
  <id_info>
    <org_study_id>1002A2828</org_study_id>
    <nct_id>NCT01126970</nct_id>
  </id_info>
  <brief_title>Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects</brief_title>
  <official_title>A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat
      administered individually or combined three times per day for 24 weeks while on a reduced
      calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit
      (S-2367), velneperit (S-2367) tert-butyl OH, and velneperit (S-2367) tert-butyl OH-O
      glucuronide following 400 mg of velneperit (S-2367) three times per day and 120 mg of
      orlistat, either combined or separate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint was the change from baseline in body weight (kg) over the 168-day (24-week) double-blind treatment period, where baseline body weight was defined as the last measurement prior to randomization</measure>
    <time_frame>168 days (24 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy analysis: The proportion of subjects with (a) a 5% decrease in body weight at Visit 7 and Visit 10 and (b) percent change in body weight from baseline to each study visit was summarized by treatment group</measure>
    <time_frame>(a) Visits 7 and 10 (b) change from baseline to each study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy analysis: The change in waist &amp;amp; hip circumference (cm) from baseline to each study visit was summarized by treatment group</measure>
    <time_frame>Change from baseline to each study visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy analysis: The proportion of subjects with a decrease equal to or greater than 1 BMI unit at Visit 7 and Visit 10 was summarized by treatment group</measure>
    <time_frame>Visits 7 and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis: (a) Treatment-emergent adverse events and (b) monitoring clinical laboratory evaluations, vital signs, 12-lead electrocardiograms, and physical examinations</measure>
    <time_frame>(a) throughout the study and (b) change from baseline to each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">486</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 Tablet Placebo Velneperit and 1 Capsule Placebo Orlistat t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet 400 mg Velneperit and 1 Capsule Placebo Orlistat t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet Placebo Velneperit and 1 Capsule 120 mg Orlistat t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Tablet 400 mg Velneperit and 1 Capsule 120 mg Orlistat t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Placebo</intervention_name>
    <description>Placebo + Placebo</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg velneperit (S-2367) + Placebo</intervention_name>
    <description>400 mg velneperit (S-2367) + Placebo</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + 120 mg Orlistat</intervention_name>
    <description>Placebo + 120 mg Orlistat</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg velneperit (S-2367) + 120 mg Orlistat</intervention_name>
    <description>400 mg velneperit (S-2367) + 120 mg Orlistat</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 65 years of age at the time of informed consent

          -  Body mass index (BMI) of 30.0 to 45.0 kg/m2 inclusive. BMI for study inclusion must
             be obtained from the Interactive Voice Response System/Web Response System
             (IVRS/WRS). (Visit 1 body weight and height obtained prior to the single-blind period
             will be used by the IVRS/WRS in the calculation.)

          -  Weight that has not fluctuated by more than 3% for the 90 days prior to Visit 1

          -  Non-smoker and no use of tobacco or nicotine products for at least 1 year prior to
             Visit 1

          -  Normotensive or acceptable level of hypertension, defined as systolic &lt;160 and
             diastolic &lt;95 mmHg

          -  No clinically significant laboratory abnormalities

          -  Negative urine drug screen for drugs of abuse

          -  No clinically significant findings on medical history, physical examination, and
             electrocardiogram (ECG) and no known history of clinically significant ECG
             abnormalities

          -  Negative serum pregnancy test in women of child-bearing potential (Females must be at
             least one year post-partum.)

          -  Males either should remain abstinent, be sterile or agree to use an approved method
             of contraception (which for males includes use of a condom with spermicide) Visit 1
             through 12 weeks following the last dose, in addition to having a female partner use
             an effective form of contraception as noted below

          -  All female subjects must be non-pregnant (confirmed by a negative serum pregnancy
             test), have no plans of becoming pregnant during the study, and must be at least one
             year post-partum, non-lactating, postmenopausal, (defined as cessation of regular
             menstrual periods for at least one year and confirmed by a follicle-stimulating
             hormone test), or surgically sterile by hysterectomy and/or bilateral oophorectomy or
             tubal ligation. Females of child-bearing potential must agree to use acceptable forms
             of birth control including oral, implantable or transdermal contraceptives; or use of
             one of the following double-barrier methods: intrauterine device with spermicide,
             diaphragm with spermicide, cervical cap with spermicide, female condom with
             spermicide, or a male condom with spermicide by the male sexual partner

          -  Able to comply with all required study procedures and schedule

          -  Able to speak and read English

          -  Signed and dated informed consent form prior to any study-related procedures

        Exclusion Criteria:

          -  Obesity of known endocrine or genetic origin (eg, hypothyroidism, Cushing's syndrome
             or diagnosed polycystic ovarian syndrome) meeting one of the following conditions:

               -  Menstrual irregularity due to oligo- or anovulation

               -  Evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern
                  balding) or biochemical (high serum androgen concentrations)

               -  Exclusion of other causes of hyperandrogenism and menstrual irregularity, such
                  as congenital adrenal hyperplasia, androgen-secreting tumors, and
                  hyperprolactinemia]

          -  History of malignancy within the previous 5 years with the exception of non-melanoma
             skin cancer or surgically cured cervical cancer

          -  Human immunodeficiency virus (HIV) identified by history or previous HIV test

          -  Any serious medical condition that, in the opinion of the Investigator, would limit
             the subject's ability to complete and/or participate in this clinical study including
             any clinically significant findings from medical history, physical examination,
             12-lead ECG, and vital signs

          -  Known history or evidence of a psychiatric disorder that in the opinion of the
             investigator would preclude the subject from participating in the trial. Stable or
             controlled anxiety or depression are permitted. Treatment with an antidepressant or
             anxiolytic drug is permitted if in accordance with Appendix 4. Subjects with a score
             of 11 or higher on the depression portion of the Hospital Anxiety and Depression
             Scale are excluded.

          -  Subjects with pancreatitis or chronic pancreatic inflammation

          -  History of Type 1 or Type 2 diabetes mellitus as defined by HbA1c &gt; 6.5% or blood
             glucose values of &gt; 126 mg/dl or treated Type 2 diabetes mellitus

          -  Any weight gain during the single-blind lead-in period (Visit 1 and Visit 3)

          -  History of surgical or device (eg, gastric bypass) intervention for obesity surgery,
             stomach banding surgery, or any other surgical procedure(s) that attempt to
             promote/aid weight loss. Note: Liposuction will be allowed if done more than 90 days
             prior to screening

          -  History of alcoholism or drug addiction/substance abuse within 1 year of Visit 1.
             Note: No alcohol consumption is permitted within 48 hours prior to blood collections
             for analysis of lipid profiles.

          -  Abnormal thyroid stimulating hormone level at screening

          -  Subjects with hypothyroidism

          -  Subjects with genetic hematologic disease or trait with or without manifestation of
             disease.

          -  Use of chronic medications/products within 90 days prior to Visit 1 or during the
             study that are known to cause weight gain. Investigators will discuss with the
             Sponsor's Medical Monitor any concomitant medications about which they are uncertain.

          -  Use of systemic corticosteroids or Depo ProveraÂ®

          -  History of fenfluramine or dexfenfluramine (Fen-Phen) administration (except with a
             prior documented echocardiogram showing no valvular abnormalities.)

          -  History of participation in any weight loss program within 90 days prior to Visit 1

          -  Participation in any weight loss medication/product study in which receipt of weight
             loss medication/product occurred within 90 days prior to Visit 1

          -  Use of any prescription or nonprescription over the counter medication/product or
             herbal/phytotherapeutic/plant-derived medications/products for weight loss, appetite
             suppression, weight control or treat obesity (includes investigational products)
             within 90 days prior to Visit 1 or during the study

          -  Subjects with cholestasis or chronic malabsorption

          -  Donation of blood or blood products 90 days prior to Visit 1 or during the study

          -  Exposure to an investigative medication within the past 30 days or 5 half-lives,
             whichever is longer or concurrent participation in any clinical trial

          -  Previous velneperit (S-2367) or other neuropeptide Y (NPY) Y5 agonist or antagonist
             use

          -  Any acute or chronic condition that, in the opinion of the Investigator, would limit
             the subject's ability to complete and/or participate in this clinical study

          -  Positive Hepatitis B or C serology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>September 13, 2011</lastchanged_date>
  <firstreceived_date>May 17, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Shionogi Clinical Trials Administrator</name_title>
    <organization>Shionogi</organization>
  </responsible_party>
  <keyword>reduced calorie diet</keyword>
  <keyword>orlistat</keyword>
  <keyword>velneperit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
